Complement C3 and its polymorphism: Biological and clinical consequences

Pathology

Volumn 46, Issue 1, 2014, Pages 1-10

  Delanghe, Joris R ^a   Speeckaert, Reinhart ^a   Speeckaert, Marijn M ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Complement C3; Immune system; Polymorphism

Indexed keywords

COMPLEMENT COMPONENT C3;

ALLELE; GENETIC DISORDER; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; HUMAN; PHENOTYPE; TRANSPLANTATION;

ALLELES; COMPLEMENT C3; GENETIC DISEASES, INBORN; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PHENOTYPE; POLYMORPHISM, GENETIC; TRANSPLANTATION;

EID: 84896784026     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0000000000000042     Document Type: Article

References (121)

1. Müller-Eberhard H.J., Schreiber RD Molecular biology and chemistry of the alternative pathway of complement. Adv Immuno. 1980; 29: 1-53.
2. Sahu A, Lambris JD Structure and biology of complement protein C3, a connecting link between innate and acquired immunity. Immunol Rev 2001; 180: 35-48.
3. Klos A, Wende E, Wareham K.J., Monk PN International Union of pharmacology. LXXXVII. Complement peptide C5a, C4a, and C3a receptors. Pharmacol Rev 2013; 65: 500-43.
4. Onat A, Can G, Rezvani R., Cianflone K. Complement C3 and cleavage products in cardiometabolic risk. Clin Chim Acta 2011; 412: 1171-9.
5. Carroll MC. The role of complement and complement receptors in induction and regulation of immunity. Ann Rev Immuno. 1998; 16: 545-68.
6. Sahu A, Isaacs SN, Soulika A.M., Lambris JD Interaction of vaccinia virus complement control protein with human complement proteins: factor Imediated degradation of C3b to iC3b1 inactivates the alternative complement pathway. J Immuno. 1998; 160: 5596-604.
7. Ross GD, Lambris JD, Cain J.A., Newman SL Generation of three different fragments of bound C3 with purified factor I or serum. I. Requirements for factor H vs CR1 cofactor activity. J Immuno. 1982; 129: 2051-60.
8. Medicus RG, Melamed J, Arnaout MA Role of human factor I and C3b receptor in the cleavage of surface-bound C3bi molecules. Eur J Immuno. 1983; 13: 465-70.
9. Davis AE 3rd, Harrison RA. Structural characterization of factor I mediated cleavage of the third component of complement. Biochemistry 1982; 21: 5745-9.
10. Einstein LP, Hansen PJ, Ballow M, et al Biosynthesis of the third component of complement (C3) in vitro by monocytes from both normal and homozygous C3-deficient humans. J Clin Invest 1977; 60: 963-9.
11. Colten HR, Ooi YM, Edelson PJ Synthesis and secretion of complement proteins by macrophages. Ann N Y Acad Sci 1979; 332: 482-90.
12. Yu CL, Tsai CY, Hsieh S.C., et al Production of the third component of complement (C3) by peripheral polymorphonuclear neutrophils of the patients with rheumatoid arthritis. Proc Natl Sci Counc Repub China B 1995; 19: 225-32.
13. Kwan WH, van der Touw W, Heeger PS. Complement regulation of T cell immunity. Immunol Res 2012; 54: 247-53.
14. van Kooten C., Fiore N, Trouw L.A., et al Complement production and regulation by dendritic cells: molecular switches between tolerance and immunity. Mol Immuno. 2008; 45: 4064-72.
15. Tang S, Zhou W, Sheerin N.S., Vaughan RW, Sacks SH Contribution of renal secreted complement C3 to the circulating pool in humans. J Immuno. 1999; 162: 4336-41.
16. Klos A, Tenner AJ, Johswich K.O., Ager RR, Reis ES, Köhl J. The role of the anaphylatoxins in health and disease. Mol Immuno. 2009; 46: 2753-66.
17. Sheerin NS, Risley P, Abe K., et al Synthesis of complement protein C3 in the kidney is an important mediator of local tissue injury. FASEB J 2008; 22: 1065-72.
18. Sacks SH, Zhou W. The role of complement in the early immune response to transplantation. Nat Rev Immuno. 2012; 12: 431-42.
19. Al-Sharif W.Z., Sunyer JO, Lambris J.D., Smith LC Sea urchin coelomocytes specifically express a homologue of the complement component C3. J Immuno. 1998; 160: 2983-97.
20. Whitehead AS, Solomon E, Chambers S., Bodmer WF, Povey S, Fey G. Assignment of the structural gene for the third component of human complement to chromosome 19. Proc Natl Acad Sci USA 1982; 79: 5021-5.
21. de Bruijn M.H., Fey GH Human complement component C3: cDNA coding sequence and derived primary structure. Proc Natl Acad Sci USA 1985; 82: 708-12.
22. Misumi Y, Oda K, Fujiwara T., Takami N, Tashiro K, Ikehara Y. Functional expression of furin demonstrating its intracellular localization and endoprotease activity for processing of proalbumin and complement pro-C3. J Biol Chem 1991; 266: 16954-9.
23. Hase S, Kikuchi N, Ikenaka T., Inoue K. Structures of sugar chains of the third component of human complement. J Biochem 1985; 98: 863-74.
24. Hirani S, Lambris JD, Müller-Eberhard HJ. Structural analysis of the asparagine-linked oligosaccharides of human complement component C3. Biochem J 1986; 233: 613-6.
25. Law SK, Dodds AW The internal thioester and the covalent binding properties of the complement proteins C3 and C4. Protein Sci 1997; 6: 263-74.
26. Lambris JD. The multifunctional role of C3, the third component of complement. Immunol Today 1988; 9: 387-93.
27. Davis AE, Harrison RA, Lachmann PJ Physiologic inactivation of fluid phase C3b: isolation and structural analysis of C3c, C3d, g (alpha 2D), and C3g. J Immuno. 1984; 132: 1960-6.
28. Lachmann PJ, Pangburn MK, Oldroyd RG Breakdown of C3 after complement activation. Identification of a new fragment C3g, using monoclonal antibodies. J Exp Med 1982; 156: 205-2016.
29. Phatsara C, editor. Analyses of Immune Competence Traits and their Association with Candidate Genes in Pigs. Göttingen: Cuvillier Verlag, 2007.
30. Fink PC, Römer M, Haeckel R., et al Measurement of proteins with the Behring Nephelometer. A multicentre evaluation. J Clin Chem Clin Biochem 1989; 27: 261-76.
31. Zegers I, Keller T, Schreiber W., et al Characterization of the new serum protein reference material ERM-DA470k/IFCC: value assignment by immunoassay. Clin Chem 2010; 56: 1880-8.
32. Yonemasu K, Kitajima H, Tanabe S., Ochi T, Shinkai H. Effect of age on C1q and C3 levels in human serum and their presence in colostrum. Immunology 1978; 35: 523-30.
33. Széplaki G., Prohászka Z, Duba J., et al Association of high serum concentration of the third component of complement (C3) with preexisting severe coronary artery disease and new vascular events in women. Atherosclerosis 2004; 177: 383-9.
34. Butts WC, James GE, Keuhneman M. Intra-individual variation in the concentrations of IgA, IgG, IgM, and complement component C3 in serum of a normal adult population. Clin Chem 1977; 23: 511-4.
35. Ram S, Lewis LA, Rice PA Infections of people with complement deficiencies and patients who have undergone splenectomy. Clin Microbiol Rev 2010; 23: 740-80.
36. Tichaczek-Goska D. Deficiencies and excessive human complement system activation in disorders of multifarious etiology. Adv Clin Exp Med 2012; 21: 105-14.
37. Gabrielsson BG, Johansson JM, Lönn M, et al High expression of complement components in omental adipose tissue in obese men. Obes Res 2003; 11: 699-708.
38. Langlois M, Delanghe J. Biological and clinical significance of haptoglobin polymorphism in man. Clin Chem 1996; 42: 1589-600.
39. Kasvosve I, Delanghe JR, Gomo ZAR, et al Transferrin polymorphism influences iron status in blacks. Clin Chem 2000; 46: 1535-9.
40. Speeckaert M, Huang G, Delanghe J., Taes YEC. Biological and clinical aspects of the vitamin D binding protein (Gc-globulin) and its polymorphism. Clin Chim Acta 2006; 372: 33-42.
41. Kasvosve I, Speeckaert M, Speeckaert R., Masukume G, Delanghe J. Haptoglobin polymorphism and infection. Adv Clin Chem 2010; 50: 23-46.
42. Delanghe J, Speeckaert M, De Buyzere ML, Langlois M, Torck M. Human plasma protein polymorphisms and the persistence of cultural diversity. PNAS USA 2012; 109: E2914.
43. Teisberg P. High voltage agarose gel electrophoresis in the study of C 3 polymorphism. Vox Sang 1970; 19: 47-56.
44. Alper CA, Propp RP Genetic polymorphism of the third component of human complement (C'3). J Clin Invest 1968; 47: 2181-91.
45. Poznansky MC, Clissold PM, Lachmann PJ The difference between human C3F and C3S results from a single amino acid change from an asparagine to an aspartate residue at position 1216 on the alpha chain of the complement component, C3. J Immuno. 1989; 143: 3860-2.
46. Rahimi AG, Goedde HW, Flatz G, et al Serum protein polymorphisms in four populations of Afghanistan. Am J Hum Genet 1977; 29: 356-60.
47. Gigante PR, Kotchetkov IS, Kellner C.P., et al Polymorphisms in complement component 3 (C3F) and complement factor H (Y402H) increase the risk of postoperative neurocognitive dysfunction following carotid endarterectomy. J Neurol Neurosurg Psychiatry 2011; 82: 247-53.
48. Schwamborn J, Freis H, Mauff G. C3 polymorphism in polyacrylamidegel electrophoresis. Vox Sang 1976; 30: 223-30.
49. Gochman N, Burke MD Electrophoretic techniques in today's clinical laboratory. Clin Lab Med 1986; 6: 403-26.
50. De Witte E., Speeckaert MM, Van De Moortel L, Lecocq E, Delanghe JR. Human complement factor 3 polymorphism by capillary electrophoresis of serum. Electrophoresis 2011; 33: 4440-4.
51. Botto M, Fong KY, So A.K., Koch C., Walport MJ Molecular basis of polymorphisms of human complement component C3. J Exp Med 1990; 172: 1011-7.
52. Brown KM, Kondeatis E, Vaughan R.W., et al Influence of donor C3 allotype on late renal-transplantation outcome. N Engl J Med 2006; 354: 2014-23.
53. Peruzzi B, Serra M, Pescucci C., et al Easy genotyping of complement C3 'slow' and 'fast' allotypes by tetra-primer amplification refractory mutation system PCR. Mol Cell Probes 2010; 24: 401-2.
54. Arvilommi H. Capacity of complement c3 phenotypes to bind on to mononuclear cells in man. Nature 1974; 251: 740-1.
55. Welch TR, Beischel L, Kleesattel A. Functional consequences of the genetic polymorphism of the third component of complement. J Pediatr 1990; 116: S92-7.
56. Bartók I., Walport MJ Comparison of the binding of C3S and C3F to complement receptors types 1, 2, and 3. J Immuno. 1995; 154: 5367-75.
57. Finn JE, Mathieson PW Molecular analysis of C3 allotypes in patients with nephritic factor. Clin Exp Immuno. 1993; 91: 410-4.
58. Sethi S, Fervenza FC, Zhang Y, Smith RJ Secondary focal and segmental glomerulosclerosis associated with single-nucleotide polymorphisms in the genes encoding complement factor H and C3. Am J Kidney Dis 2012; 60: 316-21.
59. Kim Y, Miller K, Michael AF Breakdown products of C3 and factor B in hemolytic-uremic syndrome. J Lab Clin Med 1977; 89: 845-50.
60. Le Quintrec M., Roumenina L, Noris M., Frémeaux-Bacchi V. Atypical hemolytic uremic syndrome associated with mutations in complement regulator genes. Semin Thromb Hemost 2010; 36: 641-52.
61. Frémeaux-Bacchi V., Miller EC, Liszewski M.K., et al Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood 2008; 112: 4948-52.
62. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. NEngl J Med 2009; 361: 1676-87.
63. Martínez-Barricarte R., Heurich M, Valdes-Cañedo F, et al. Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. J Clin Invest 2010; 120: 3702-12.
64. Torreira E, Tortajada A, Montes T., Rodríguez de Córdoba S, Llorca O. 3D structure of the C3bB complex provides insights into the activation and regulation of the complement alternative pathway convertase. Proc Natl Acad Sci USA 2009; 106: 882-7.
65. Abrera-Abeleda M.A., Nishimura C, Frees K., et al Allelic variants of complement genes associated with dense deposit disease. J Am Soc Nephrol 2011; 22: 1551-9.
66. Moller DE, Kaufman KD Metabolic syndrome: a clinical and molecular perspective. Annu Rev Med 2005; 56: 45-62.
67. Engstrom G, Hedblad B, Eriksson K.F., Janzon L., Lindgarde F. Complement C3 is a risk factor for the development of diabetes: a population based cohort study. Diabetes 2005; 54: 570-5.
68. van Oostrom A.J., Alipour A, Plokker T.W., Sniderman AD, Cabezas MC The metabolic syndrome in relation to complement component 3 and postprandial lipemia in patients from an outpatient lipid clinic and healthy volunteers. Atherosclerosis 2007; 190: 167-73.
69. Wlazlo N, van Greevenbroek MM, Ferreira I, et al Low-grade inflammation and insulin resistance independently explain substantial parts of the association between body fat and serum C3: the CODAM study. Metabolism 2012; 61: 1787-96.
70. Hertle E, van Greevenbroek MM, Stehouwer CD Complement C3: an emerging risk factor in cardiometabolic disease. Diabetologia 2012; 55: 881-4.
71. Phillips CM, Goumidi L, Bertrais S., et al Complement component 3 polymorphisms interact with polyunsaturated fatty acids to modulate risk of metabolic syndrome. Am J Clin Nutr 2009; 90: 1665-73.
72. Elmgreen J, Sørensen H, Berkowicz A. Polymorphism of complement C3 in chronic inflammatory bowel disease. Predominance of the C3F gene in Crohn's disease. Acta Med Scand 1984; 215: 375-8.
73. Van Timmeren M.M., Chen M, Heeringa P. Review article: Pathogenic role of complement activation in anti-neutrophil cytoplasmic autoantibody-associated vasculitis. Nephrology (Carlton) 2009; 14: 16-25.
74. Persson U, Truedsson L, Westman K.W., Segelmark M. C3 and C4 allotypes in anti-neutrophil cytoplasmic autoantibody (ANCA)-positive vasculitis. Clin Exp Immunol 1999; 116: 379-82.
75. Finn JE, Zhang L, Agrawal S., Jayne DR, Oliveira DB, Mathieson PW Molecular analysis of C3 allotypes in patients with systemic vasculitis. Nephrol Dial Transplant 1994; 9: 1564-7.
76. Pickering MC, Walport MJ Links between complement abnormalities and systemic lupus erythematosus. Rheumatology (Oxford) 2000; 39: 133-41.
77. Miyagawa H, Yamai M, Sakaguchi D., et al Association of polymorphisms in complement component C3 gene with susceptibility to systemic lupus erythematosus. Rheumatology (Oxford) 2008; 47: 158-64.
78. Rhodes B, Hunnangkul S, Morris D.L., et al The heritability and genetics of complement C3 expression in UK SLE families. Genes Immun 2009; 10: 525-30.
79. Bassig BA, Zheng T, Zhang Y., et al Polymorphisms in complement system genes and risk of non-Hodgkin lymphoma. Environ Mol Mutagen 2012; 53: 145-51.
80. Cerhan JR, Novak AJ, Fredericksen Z.S., et al Risk of non-Hodgkin lymphoma in association with germline variation in complement genes. Br J Haematol 2009; 145: 614-23.
81. Purwar R, Langer K, Werfel T. Polymorphisms within the C3 gene are associated with specific IgE levels to common allergens and superantigens among atopic dermatitis patients. Exp Dermatol 2009; 18: 30-4.
82. Acevedo F, Hammar H. Complement C3 proteins in psoriasis. Br J Dermatol 1989; 121: 329-35.
83. Cisło M., Hałasa J, Wasik F., et al Allelic distribution of complement components BF, C4A, C4B, and C3 in Psoriasis vulgaris. Immunol Lett 2002; 80: 145-9.
84. Levy Y, George J, Yona E., Shoenfeld Y Partial lipodystrophy, mesangiocapillary glomerulonephritis, and complement dysregulation. An autoimmune phenomenon. Immunol Res 1998; 18: 55-60.
85. Hasegawa K, Tamari M, Shao C., et al Variations in the C3, C3a receptor, and C5 genes affect susceptibility to bronchial asthma. Hum Genet 2004; 115: 295-301.
86. Inoue H, Mashimo Y, Funamizu M., et al Association study of the C3 gene with adult and childhood asthma. J Hum Genet 2008; 53: 728-38.
87. Kohl J, Wills-Karp M. A dual role for complement in allergic asthma. Curr Opin Pharmacol 2007; 7: 283-9.
88. Blumenthal MN, Ober C, Beaty T.H., et al Genome scan for loci linked to mite sensitivity: the Collaborative Study on the Genetics of Asthma (CSGA). Genes Immunity 2004; 5: 226-31.
89. Drouin SM, Corry DB, Kildsgaard J, Wetsel RA Cutting edge: the absence of C3 demonstrates a role for complement in Th2 effector functions in a murine model of pulmonary allergy. J Immunol 2001; 167: 4141-5.
90. Nakano Y, Morita S, Kawamoto A., Suda T, Chida K, Nakamura H. Elevated complement C3a in plasma from patients with severe acute asthma. J Allergy Clin Immunol 2003; 112: 525-30.
91. Krug N, Tschernig T, Erpenbeck V.J., Hohlfeld JM, Kohl J. Complement factors C3a and C5a are increased in bronchoalveolar lavage fluid after segmental allergen provocation in subjects with asthma. Am J Respir Crit Care Med 2001; 164: 1841-3.
92. Barnes KC, Grant AV, Baltadzhieva D, et al Variants in the gene encoding C3 are associated with asthma and related phenotypes among African Caribbean families. Genes Immun 2006; 7: 27-35.
93. Undarmaa S, Mashimo Y, Hattori S., et al Replication of genetic association studies in asthma and related phenotypes. J Hum Genet 2010; 55: 342-9.
94. Leban N, Haj Khelil A, Daimi H, et al C3 complement polymorphism in patients suffering from obstructive chronic bronchopneumopathy in Tunisia. Ann Biol Clin (Paris) 2007; 65: 251-6.
95. Senbagavalli P, Kumar N, Kaur G., Mehra NK, Geetha ST, Ramanathan VD Major histocompatibility complex class III (C2, C4, factor B) and C3 gene variants in patients with pulmonary tuberculosis. Hum Immuno. 2011; 72: 173-8.
96. Okroj M, Hsu YF, Ajona D, Pio R., Blom AM Non-small cell lung cancer cells produce a functional set of complement factor I and its soluble cofactors. Mol Immuno. 2008; 45: 169-79.
97. Markiewski MM, Lambris JD Is complement good or bad for cancer patients? A new perspective on an old dilemma. Trends Immuno. 2009; 30: 286-92.
98. Suadicani P, Hein H, Gyntelberg F. Complement C3 Genotype Variants and Risk of Lung Cancer Mortality. ISRN Pulmonology 2011; 2011: 1-4.
99. Olsson S, Stokowska A, Holmegaard L., et al Genetic variation in complement component C3 shows association with ischaemic stroke. Eur J Neurol 2011; 18: 1272-4.
100. Ostergaard JR, Bruun-Petersen G, Kristensen BO The C3-F gene in patients with intracranial saccular aneurysms. Acta Neurol Scand 1986; 74: 356-9.
101. Schaadt O, Sørensen H, Krogsgaard AR. Association between the C3F-gene and essential hypertension. Clin Sci (Lond) 1981; 61 (Suppl 7): 363s-5s.
102. Engström G., Hedblad B, Berglund G., Janzon L, Lindgärde F. Plasma levels of complement C3 is associated with development of hypertension: a longitudinal cohort study. J Hum Hypertens 2007; 21: 276-82.
103. Magen E, Feldman A, Cohen Z., et al Potential link between C3a, C3b and endothelial progenitor cells in resistant hypertension. Am J Med Sci 2010; 339: 415-9.
104. Muscari A, Massarelli G, Bastagli L., et al Relationship between serum C3 levels and traditional risk factors for myocardial infarction. Acta Cardiol 1998; 53: 345-54.
105. Muscari A, Massarelli G, Puddu G.M., et al Serum C3 as a screening factor in the primary prevention of myocardial infarct. Cardiologia 1995; 40: 507-14.
106. Kristensen BP, Petersen GB Association between coronary heart disease and the C3F-gene in essential hypertension. Circulation 1978; 58: 622-5.
107. Messias-Reason I.J., Urbanetz L, Pereira da Cunha C. Complement C3 F and BF S allotypes are risk factors for Chagas disease cardiomyopathy. Tissue Antigens 2003; 62: 308-12.
108. Pratt JR, Basheer SA, Sacks SH Local synthesis of complement component C3 regulates acute renal transplant rejection. Nat Med 2002; 8: 582-7.
109. Hoffmann S, Park J, Jacobson L.M., et al Donor genomics influence graft events: the effect of donor polymorphisms on acute rejection and chronic allograft nephropathy. Kidney Int 2004; 66: 1686-93.
110. Varagunam M, Yaqoob MM, Döhler B, Opelz G. C3 polymorphisms and allograft outcome in renal transplantation. N Engl J Med 2009; 360: 874-80.
111. Andrews PA, Finn JE, Mathieson P.W., Sacks SH Molecular analysis of C3 allotypes related to transplant outcome in human renal allografts. Transplantation 1995; 60: 1342-6.
112. Naesens M, Butte AJ, Sarwal MM C3 polymorphisms and outcomes of renal allografts. N Engl J Med 2009; 360: 2478.
113. Damman J, Daha MR, Leuvenink H.G., et al Association of complement C3 gene variants with renal transplant outcome of deceased cardiac dead donor kidneys. Am J Transplant 2012; 12: 660-8.
114. Pallet N, Thervet E. The genetics of kidney transplantation. Hum Genet 2012; 131: 317-23.
115. Dhillon N, Walsh L, Krüger B, Mehrotra A., et al Complement component C3 allotypes and outcomes in liver transplantation. Liver Transpl 2010; 16: 198-203.
116. de Jong PTVM. Age-related macular degeneration. N Engl J Med 2006; 355: 1474-85.
117. Yates JR, Sepp T, Matharu B.K., et al Genetic Factors in AMD Study GroupComplement C3 variant and the risk of age-related macular degeneration. N Engl J Med 2007; 357: 553-61.
118. Despriet DD, van Duijn CM, Oostra BA, et al Complement component C3 and risk of age-related macular degeneration. Opthalmology 2009; 116: 474-80.
119. McKay GJ, Dasari S, Patterson C.C., Chakravarthy U., Silvestri G. Complement Component 3: an assessment of association with AMD and analysis of gene-gene and gene-environment interactions in a Northern Irish cohort. Mol Vis 2010; 16: 194-9.
120. Mullins RF, Russell SR, Anderson D.H., Hageman GS Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. FASEB J 2000; 14: 835-46.
121. Johnson PT, Betts KE, Radeke M.J., Hageman GS, Anderson DH, Johnson LV Individuals homozygous for the age-related macular degeneration risk-conferring variant of complement factor H have elevated levels of CRP in the choroid. Proc Natl Acad Sci USA 2006; 103: 17456-61.